Calcium antagonists: Do they equally protect against kidney injury?

Kidney International

Volumn 73, Issue 7, 2008, Pages 795-796

  Hart, P ^a   Bakris, G L ^b,c  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; ENALAPRIL; IMIDAPRIL; LISINOPRIL; NIFEDIPINE; VERAPAMIL;

CHRONIC KIDNEY DISEASE; DISEASE MARKER; DRUG EFFICACY; DRUG INDICATION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 40849130229     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002773     Document Type: Note

References (19)

1. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46: 161-169.
2. Bakris GL, Weir MR, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991-2002.
3. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889-896.
4. Boero R, Rollino C, Massara C et al. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis 2003; 42: 67-75.
5. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793-800.
6. Griffin KA, Hacioglu R, bu-Amarah I et al. Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation. Am J Physiol Renal Physiol 2004; 286: F1136-F1143.
7. Bidani AK, Griffin KA. Calcium channel blockers and renal protection: is there an optimal dose? J Lab Clin Med 1995; 125: 553-555.
8. Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
9. Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-244.
10. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
11. Shudo C, Masuda Y, Sugita H et al. Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats. Arzneimittelforschung 1996; 46: 852-854.
12. Sugano N, Wakino S, Kanda T et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008; 73: 826-834.
13. Ito S, Kume H, Oguma T et al. Roles of stretch-activated cation channel and Rho-kinase in the spontaneous contraction of airway smooth muscle. Eur J Pharmacol 2006; 552: 135-142.
14. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005; 46: 637-642.
15. Kloke HJ, Wetzels JF, Koene RA, Huysmans FT. Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease. Nephrol Dial Transplant 1998; 13: 646-650.
16. Hunsicker LG, Atkins RC, Lewis JB et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; S99-S101.
17. Wright JT Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
18. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. KDOQI. Am J Kidney Dis 2007; 49: S12-S154.
19. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Kidney Disease Outcomes Quality Initiative (K/DOQI). Am J Kidney Dis 2004; 43: 1-290.